Description: Humanized Monoclonal Antibody.human IgM

Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection.

Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

Description: N/A

Description: N/A

Description: Primary VHH single domain antibody

Description: Primary VHH single domain antibody

Description: Primary VHH single domain antibody

Description: Primary VHH single domain antibody

Description: Primary VHH single domain antibody

Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Description: Recombinant humanised version of the mouse monoclonal antibody MAB12447. Antibody is specific for SARS-CoV-2 spike subunit 2 protein.

Description: Recombinant humanised version of the mouse monoclonal antibody MAB12447. Antibody is specific for SARS-CoV-2 spike subunit 2 protein.

Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus and other viral lineages.

Description: Recombinant humanized monoclonal antibody of the mouse monoclonal antibody MAB12446, against SARS-CoV-2 spike subunit 2 (S2) protein.

Description: Recombinant humanized monoclonal antibody of the mouse monoclonal antibody MAB12446, against SARS-CoV-2 spike subunit 2 (S2) protein.

Description: This is a recombinant monoclonal antibody. It is a reformatted human antibody made using the variable domain sequences of the original Human IgG1 format.

Description: The Human Anti-SARS-CoV-2 Spike RBD Antibody-coupled Magnetic Beads is produced by coupling biotinylated anti-RBD antibody to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing spike protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.